BIOAGE LABS, INC. Interest Expense Nonoperating
BIOAGE LABS, INC. (BIOA) reported Interest Expense Nonoperating of $1.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- BIOAGE LABS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $1.00K, a 99.50% decline year-over-year.
- BIOAGE LABS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $39.00K, a 84.71% decline year-over-year.
- BIOAGE LABS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $92.00K, a 71.16% decline year-over-year.
- BIOAGE LABS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $149.00K, a 61.60% decline year-over-year.
- BIOAGE LABS, INC. interest expense nonoperating for fiscal 2025 was $697.00K, a 70.55% decline from fiscal 2024.
- BIOAGE LABS, INC. interest expense nonoperating for fiscal 2024 was $2.37M, a 69.63% decline from fiscal 2023.
- BIOAGE LABS, INC. interest expense nonoperating for fiscal 2023 was $7.79M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00K 10-Q · filed 2026-08-05 | $40.00K 10-Q · filed 2026-08-05 | $132.00K derived: sum of 3 quarters · filed 2026-08-05 | $281.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $39.00K 10-Q · filed 2026-05-08 | $131.00K derived: sum of 2 quarters · filed 2026-05-08 | $280.00K derived: sum of 3 quarters · filed 2026-05-08 | $481.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $241.00K derived: sum of 2 quarters · filed 2026-03-24 | $442.00K derived: sum of 3 quarters · filed 2026-08-05 | $697.00K 10-K · filed 2026-03-24 |
| 2025-09-30 | $149.00K 10-Q · filed 2025-11-06 | $350.00K derived: sum of 2 quarters · filed 2026-08-05 | $605.00K 10-Q · filed 2025-11-06 | $924.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $201.00K 10-Q · filed 2026-08-05 | $456.00K 10-Q · filed 2026-08-05 | $775.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $255.00K 10-Q · filed 2026-05-08 | $574.00K derived: sum of 2 quarters · filed 2026-05-08 | $962.00K derived: sum of 3 quarters · filed 2026-05-08 | $1.41M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $319.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $707.00K derived: sum of 2 quarters · filed 2026-03-24 | $1.15M derived: sum of 3 quarters · filed 2026-03-24 | $2.37M 10-K · filed 2026-03-24 |
| 2024-09-30 | $388.00K 10-Q · filed 2025-11-06 | $831.00K derived: sum of 2 quarters · filed 2025-11-06 | $2.05M 10-Q · filed 2025-11-06 | $4.61M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $443.00K 10-Q · filed 2025-08-06 | $1.66M 10-Q · filed 2025-08-06 | $4.22M derived: sum of 3 quarters · filed 2025-08-06 | $6.62M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $1.22M 10-Q · filed 2025-05-06 | $3.78M derived: sum of 2 quarters · filed 2025-05-06 | $6.18M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $4.96M derived: sum of 2 quarters · filed 2025-03-20 | $7.79M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $2.40M 10-Q · filed 2024-11-07 | $5.24M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |